TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require this therapy are being treated with anticoagulants (AC).

Anticoagulación y TAVI

Even though the current guidelines suggest interrupting anticoagulation to reduce bleeding risk, the available evidence has not yet fully elucidated this recommendation. 

This analysis of POPular PAUSE TAVI, included 858 patients treated with anticoagulants undergoing TAVR. 431 (50.2%) of these patients continued with AC (AC+), while the rest stopped AC and continued after procedure, according to treating physician criteria (AC-). 

The primary outcome was a composite of cardiovascular death, stroke, infarction, vascular complications or major bleeding within 30 days after procedure. 

Baseline group characteristics were similar: mean age 81, one third women, 3.8 STS Score, atrial fibrillation in 96% of cases, 4.5 CHA2DS2-VASc Score, 78% were hypertensive, 30% diabetic, 33% had a history of CABG, 15% had infarction history, 11% stroke, 10% TIA, 13% COPD, there was kidney function deterioration in 50% and prior TAVR in 7%.

Read also: RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions.

There were no differences in primary end point, with 16.5% incidence in AC+ patients vs 14.8% in AC- (risk difference: 1.7 percentual points, CI 95%: −3.1 to 6.6; P = 0.18 for non-inferiority). Neither were there differences in cardiovascular mortality, all cause stroke, infarction, major bleeding or major vascular complications. 

Conclusion

In TAVR patients, periprocedural anticoagulation was shown non-inferior vs. AC interruption as regards the incidence of the combined end point of cardiovascular death, stroke, infarction, major vascular complications and major bleeding at 30 days. 

Original Title: Continuation versus Interruption of Oral Anticoagulation during TAVI. POPular PAUSE TAVI Trial.

Reference: D.J. van Ginkel, et al. N Engl J Med 2025;392:438-49. DOI: 10.1056/NEJMoa2407794.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...